Chemotherapy induced peripheraly neuropathy
Conditions
Interventions
We prescribe mirogabalin for up to 12 weeks.
Sponsors
Sapporo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pathologically consistent with multiple myeloma, malignant lymphoma, gastric cancer, colorectal cancer, sarcoma or pancreatic cancer. 2. Patiesnts with administered Bordezomib, vincristine, platinum preparations (cisplatin, oxaliplatin), or microtubule inhibitor preparations (paclitaxel, paclitaxel, Nabupaclitaxel, docetaxel, eribulin). 3. CTCTE ver5.0 Grade 2 or more, NRS 4 points to NRS 8 points/10 points CIPN. 4. over 20 years old. 5. Informed consent had been obtained.
Exclusion criteria
Exclusion criteria: 1. Other than multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, sarcoma and pancreatic cancer. 2. CIPN of Grade 1 or lower, or NRS 3 points or lower or NRS 9 points or higher in CTCTE ver5.0. 3. CIPN thought to be caused by other than bordezomib, vincristine, platinum preparations (cisplatin, oxaliplatin), and microtubule inhibitor preparations (paclitaxel, nabupaclitaxel, docetaxel, eribulin). 4. ECOG-PS4 or poor general condition. 5. Patients who are using the following drugs in combination: antidepressants, SSRI/SNRI, antiepileptic drugs, opioids, goshajinkigan, Vitamin B12 preparations. 6. Diagnosed as severe heart disease or lung disease. 7. Diagnosed as poor renal function with creatinine clearance of less than 60 mL/min. 8. Pregnant women, lactating women or those who may be pregnant. 9. The patients who were ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS | — |
Secondary
| Measure | Time frame |
|---|---|
| CTCAE, FACT/GOS-Nt | — |
Countries
Japan
Contacts
Public ContactMAKOTO YOSHIDA
Sapporo Medical University Department of Medical Oncology
Outcome results
None listed